Prolactinoma When Escalated Dopamine Agonist Therapy Fails to Normalise Prolactin or Achieve Adequate Tumour Shrinkage

This protocol applies to patients with prolactinoma in whom dopamine agonist therapy — escalated to the maximally tolerated dose, or switched to an alternative agent due to intolerance — has still not achieved the required disease control targets.

Prior Treatment Line — Goals Not Achieved

Prior therapy: Cabergoline escalated to the maximally tolerated dose; or, where dopamine agonist intolerance was present, a switch to an alternative dopamine agonist such as quinagolide.

Targets not met: Normalisation of serum prolactin levels, and relevant tumour shrinkage (at least 30% reduction in maximum tumour diameter) — neither achieved despite the above measures.

This Protocol — Approach & Goal

For patients who have not responded adequately to maximally escalated dopamine agonist therapy, this protocol outlines a surgical pathway. Transsphenoidal surgery by an experienced neurosurgeon is central to the approach described. The complete clinical framework — including candidate selection and procedural considerations — is detailed in the full regimen.

Primary goal: Initial normoprolactinaemia — normalisation of serum prolactin levels

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/s41574-023-00886-5

Transsphenoidal surgery (TSS) performed by an experienced neurosurgeon can achieve initial normoprolactinaemia in up to 93% of individuals with microprolactinomas and 75% of those with selected macroprolactinomas.

If prolactin is not controlled even by dose escalation to maximally tolerated doses of dopamine agonists and surgery is considered for debulking, the term suggested is 'refractory' prolactinoma.

View source ↗